Jody Ciolino, PhD, and Masha Kocherginsky, PhD, faculty in the Department of Preventive Medicine Division of Biostatistics, were elected to the Board of Directors for the Society for Clinical Trials (SCT).
Browsing: Cancer
A newly discovered inhibitor of a common cancer-causing protein operates selectively, reducing expression of genes that fuel rampant cell proliferation, and altering the epigenome, according to a recent study.
A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies.
The Cancer Immunology and Immunotherapy Initiative at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University is bringing together Feinberg investigators who study immunotherapy to increase collaboration and accelerate high-impact immunotherapy research.
Investigators have discovered the mechanisms underlying a T-cell receptor’s immunosuppressive function, findings that may improve the development of precision therapeutics for chronic disease, including cancer.
William Gradishar, MD, chief of Hematology and Oncology in the Department of Medicine and deputy director of the clinical network of the Lurie Cancer Center, has received the 2022 Rodger Winn Award from the National Comprehensive Cancer Network.
A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer.
Northwestern Medicine investigators have discovered a potential therapeutic target for the most common type of pancreatic cancer, according to a study published in Developmental Cell.
A new study has identified a drug that inhibits growth of aggressive meningiomas and how to most accurately identify which tumors will respond to the drug.
Northwestern Medicine investigators have identified a gene that confers resistance to a common prostate cancer treatment, according to a study published in Cancer Research.